Randomized trial reveals predictive biomarkers for cancer stemness and immune environment in pancreatic adenocarcinoma, suggesting pathways for targeted therapy.
Key Points
This research aims to identify autophagy-related genes and their role in cancer stemness and immune response in pancreatic adenocarcinoma.
Data collected from TCGA, GTEx, and GEO for pancreatic adenocarcinoma-related analysis.
Weighted Gene Co-expression Network Analysis (WGCNA) and differential expression analysis were utilized to identify candidate genes.
Four genes (HGF, RECK, CYP1B1, ZEB2) were identified as significant biomarkers linked to autophagy and immune indicators in PAAD.
HGF, RECK, and ZEB2 showed a positive correlation with cancer stem cell scores (R > 0.3), influencing pathways such as epithelial-mesenchymal transition.
Molecular docking results indicated that CYP1B1, HGF, and RECK have stable bindings with resveratrol.